Wilson Sonsini Goodrich & Rosati advised Absci on the transaction. Absci Corporation (Nasdaq: ABSI) announced a collaboration with AstraZeneca, a global biopharmaceutical company, to deliver an AI-designed...
Absci’s Collaboration with Astrazeneca
CARGO Therapeutics’ $281.3 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
Pyxis Oncology’s Acquisition of Apexigen
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
Third Rock Ventures’ Investment in CARGO Therapeutics
Orrick advised Third Rock Ventures on the deal while Wilson Sonsini represented CARGO Therapeutics. Third Rock Ventures announced its investment in the $200 million Series A financing...
Insilico Medicine’s Research Collaboration with Sanofi
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
Novartis’ Acquisition of Kedalion Therapeutics
Wilson Sonsini advised Kedalion Therapeutics on the deal. Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the...
Chroma Medicine’s $125 Million Financing
Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
WuXi AppTec’s Acquisition of OXGENE
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...